Earnings
Home›Earnings›Previews›Novo Nordisk shares slide after heart drug trial fails…
Novo Nordisk shares slide after heart drug trial fails to show benefit
The company said ziltivekimab did not deliver a statistically meaningful reduction in major cardiovascular adverse events, according to CNBC.
Novo Nordisk shares fell after the company said an experimental heart medicine, ziltivekimab, failed to show a statistically meaningful benefit in a clinical trial.
According to CNBC Markets, Novo said the drug did not translate into a reduction in major cardiovascular adverse events, the key endpoint for the study.
CNBC World reported the same result, noting the lack of statistical significance in the cardiovascular outcomes.
← Newer storyECB’s September hike still the base case despite stronger euro inflat…Older story →Yen jumps after Japan intervenes, dragging down USDJPY